Hemispherx: FDA decision on Ampligen won't come until fall

07/23/2009 | American City Business Journals

The FDA might take until fall to decide on Hemispherx BioPharma's application for Ampligen, an experimental treatment for chronic fatigue syndrome, because of staffing problems, said Dr. William Carter, the company's president and CEO. The biotech firm, which Carter said has been communicating with the FDA since May, is in discussions with potential marketing partners while the agency reviews the product.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL